Ask AI
ProCE Banner Activity

Evaluating the Data: The Rationale for PARPi Combinations

Slideset

Downloadable slides from a live symposium covering the data supporting PARPi monotherapy and combination regimens.

Released: February 25, 2026

Continue Activity

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca. Supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

AstraZeneca

Merck & Co., Inc., Rahway, NJ, USA

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Target Audience

This activity is intended for community oncologists, urologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in the care and treatment of patients with prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate efficacy, treatment sequencing, and subgroup data from recent trials of PARPi combinations in mPC, and assess their implications across BRCA and non-BRCA HRR mutation populations

  • Formulate patient care plans with PARP inhibitor-based combination regimens for the treatment of patients with mPC, taking into account recent guideline updates for sequencing, expert recommendations, and recent data, including patient subgroup data